Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial Feb 28, 2022 | HIV
In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells Nov 5, 2018 | HIV
